Jonathan Straub, AA | |
1968 Peachtree Rd Nw, Atlanta, GA 30309-1281 | |
(404) 605-5000 | |
Not Available |
Full Name | Jonathan Straub |
---|---|
Gender | Male |
Speciality | Anesthesiology Assistant |
Experience | 15 Years |
Location | 1968 Peachtree Rd Nw, Atlanta, Georgia |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1174753545 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
367H00000X | Anesthesiologist Assistant | (* (Not Available)) | Secondary |
367H00000X | Anesthesiologist Assistant | 5705 (Georgia) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Emory Johns Creek Hospital | Johns creek, GA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Emory Specialty Associates, Llc | 3476559782 | 430 |
News Archive
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced today that the U.S. Food and Drug Administration has determined that a new drug application (NDA) for Otsuka's investigational once-monthly aripiprazole depot formulation for the indication of maintenance treatment of schizophrenia in adults is sufficiently complete to permit a substantive review.
A study published in the scientific journal PLoS ONE highlights how the exploration of the ocean depths can benefit humankind.
Should parents be able to use medical means to restrict the growth of profoundly disabled children to make them easier to care for at home. A working group convened to discuss the ethical and policy considerations of "growth attenuation" proposes some guidelines in an article in the Hastings Center Report. Personal essays including those of parents whose children cannot walk or speak accompany the article
Ember Therapeutics, Inc., a privately held, New York-based biopharmaceutical company that is developing targeted therapies for osteoarthritis, kidney fibrosis, and other indications using Bone Morphogenetic Protein (BMP)-7, announced today initial results from the Phase II(a) trial of local BMP-7 administration in patients with moderate osteoarthritis of the knee.
› Verified 9 days ago
Entity Name | The Emory Clinic Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1396798229 PECOS PAC ID: 8820901408 Enrollment ID: O20031110000503 |
News Archive
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced today that the U.S. Food and Drug Administration has determined that a new drug application (NDA) for Otsuka's investigational once-monthly aripiprazole depot formulation for the indication of maintenance treatment of schizophrenia in adults is sufficiently complete to permit a substantive review.
A study published in the scientific journal PLoS ONE highlights how the exploration of the ocean depths can benefit humankind.
Should parents be able to use medical means to restrict the growth of profoundly disabled children to make them easier to care for at home. A working group convened to discuss the ethical and policy considerations of "growth attenuation" proposes some guidelines in an article in the Hastings Center Report. Personal essays including those of parents whose children cannot walk or speak accompany the article
Ember Therapeutics, Inc., a privately held, New York-based biopharmaceutical company that is developing targeted therapies for osteoarthritis, kidney fibrosis, and other indications using Bone Morphogenetic Protein (BMP)-7, announced today initial results from the Phase II(a) trial of local BMP-7 administration in patients with moderate osteoarthritis of the knee.
› Verified 9 days ago
Entity Name | Emory Specialty Associates, Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1407864168 PECOS PAC ID: 3476559782 Enrollment ID: O20061010000447 |
News Archive
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced today that the U.S. Food and Drug Administration has determined that a new drug application (NDA) for Otsuka's investigational once-monthly aripiprazole depot formulation for the indication of maintenance treatment of schizophrenia in adults is sufficiently complete to permit a substantive review.
A study published in the scientific journal PLoS ONE highlights how the exploration of the ocean depths can benefit humankind.
Should parents be able to use medical means to restrict the growth of profoundly disabled children to make them easier to care for at home. A working group convened to discuss the ethical and policy considerations of "growth attenuation" proposes some guidelines in an article in the Hastings Center Report. Personal essays including those of parents whose children cannot walk or speak accompany the article
Ember Therapeutics, Inc., a privately held, New York-based biopharmaceutical company that is developing targeted therapies for osteoarthritis, kidney fibrosis, and other indications using Bone Morphogenetic Protein (BMP)-7, announced today initial results from the Phase II(a) trial of local BMP-7 administration in patients with moderate osteoarthritis of the knee.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Jonathan Straub, AA 671 Hillpine Dr Ne, Atlanta, GA 30306-3222 Ph: (412) 719-3086 | Jonathan Straub, AA 1968 Peachtree Rd Nw, Atlanta, GA 30309-1281 Ph: (404) 605-5000 |
News Archive
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced today that the U.S. Food and Drug Administration has determined that a new drug application (NDA) for Otsuka's investigational once-monthly aripiprazole depot formulation for the indication of maintenance treatment of schizophrenia in adults is sufficiently complete to permit a substantive review.
A study published in the scientific journal PLoS ONE highlights how the exploration of the ocean depths can benefit humankind.
Should parents be able to use medical means to restrict the growth of profoundly disabled children to make them easier to care for at home. A working group convened to discuss the ethical and policy considerations of "growth attenuation" proposes some guidelines in an article in the Hastings Center Report. Personal essays including those of parents whose children cannot walk or speak accompany the article
Ember Therapeutics, Inc., a privately held, New York-based biopharmaceutical company that is developing targeted therapies for osteoarthritis, kidney fibrosis, and other indications using Bone Morphogenetic Protein (BMP)-7, announced today initial results from the Phase II(a) trial of local BMP-7 administration in patients with moderate osteoarthritis of the knee.
› Verified 9 days ago
Matthew Lewis, PAA Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 1405 Clifton Rd Ne Fl 3, Atlanta, GA 30322 Phone: 404-785-6670 Fax: 404-785-1362 | |
Elizabeth Ikeda, Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 1365 Clifton Rd Ne, Atlanta, GA 30322 Phone: 404-778-8311 | |
Amar R Herndon, Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 1000 Johnson Ferry Rd Ne, Atlanta, GA 30342 Phone: 770-645-9181 | |
Shelley S Staton, PAAA Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 1000 Johnson Ferry Rd, Atlanta, GA 30342 Phone: 770-645-9181 Fax: 770-645-8455 | |
Mr. Grant Michael Mury, PAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 550 Peachtree St Ne, Atlanta, GA 30308 Phone: 404-778-3900 | |
Ashley Schade, PAAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 5665 Peachtree Dunwoody Rd, Atlanta, GA 30342 Phone: 706-543-3449 | |
Jiaqi Tracy Li, PAA Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 1001 Johnson Fy Rd Ne, Atlanta, GA 30342 Phone: 404-785-2008 Fax: 404-785-4496 |